← Back to Search

Virus Therapy

SARS-CoV-2 convalescent plasma for COVID-19 (CSSC-004 Trial)

Phase 2
Waitlist Available
Led By David J Sullivan, MD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 0, 14, 28 and 90
Awards & highlights

CSSC-004 Trial Summary

This trial is testing a possible treatment for coronavirus that involves using plasma from people who have recovered from the virus.

CSSC-004 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 0, 14, 28 and 90
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 0, 14, 28 and 90 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cumulative Incidence of Severe Infusion Reactions
Cumulative Incidence of Treatment-related Acute Respiratory Distress Syndrome (ARDS)
Cumulative Incidence of Treatment-related Grade 3 or Higher Adverse Events
+1 more
Secondary outcome measures
Serum SARS-CoV-2 Antibody Titers by Visit
Other outcome measures
Impact of Convalescent Plasma on Outcome as Assessed by Change in Hospitalization Rate
Impact of Donor Antibody Titers on Hospitalization Rate of Convalescent Plasma Recipients
Number of Participants Who Died
+5 more

Side effects data

From 2022 Phase 2 trial • 1225 Patients • NCT04373460
2%
Infusion related reaction
2%
Pneumonia
2%
Urticaria
1%
Pharyngitis
1%
Sinus tachycardia
1%
Fever
1%
Vasovagal reaction
1%
Non-cardiac chest pain
1%
Headache
1%
Hypertension
1%
Urinary tract infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
SARS-CoV-2 Convalescent Plasma
Standard Control Plasma

CSSC-004 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: SARS-CoV-2 convalescent plasmaExperimental Treatment1 Intervention
SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
Group II: Standard Control plasmaActive Control1 Intervention
Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SARS-CoV-2 convalescent plasma
2020
Completed Phase 3
~1310

Find a Location

Who is running the clinical trial?

National Center for Advancing Translational Science (NCATS)NIH
99 Previous Clinical Trials
35,084 Total Patients Enrolled
4 Trials studying COVID-19
17,985 Patients Enrolled for COVID-19
National Center for Advancing Translational Sciences (NCATS)NIH
321 Previous Clinical Trials
400,524 Total Patients Enrolled
20 Trials studying COVID-19
266,222 Patients Enrolled for COVID-19
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,270 Previous Clinical Trials
5,484,012 Total Patients Enrolled
78 Trials studying COVID-19
290,983 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
2020. "Convalescent Plasma to Limit SARS-CoV-2 Associated Complications". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04373460.
~253 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top